The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sabrilex     4-aminohex-5-enoic acid

Synonyms: Sabril, vigabatrin, gamma-Vinyl-GABA, gamma Vinyl GABA, Vigabatrin Aventis Brand, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Sabril


Psychiatry related information on Sabril


High impact information on Sabril


Chemical compound and disease context of Sabril


Biological context of Sabril


Anatomical context of Sabril


Associations of Sabril with other chemical compounds


Gene context of Sabril


Analytical, diagnostic and therapeutic context of Sabril


  1. Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Hogema, B.M., Gupta, M., Senephansiri, H., Burlingame, T.G., Taylor, M., Jakobs, C., Schutgens, R.B., Froestl, W., Snead, O.C., Diaz-Arrastia, R., Bottiglieri, T., Grompe, M., Gibson, K.M. Nat. Genet. (2001) [Pubmed]
  2. Vigabatrin in infantile spasms. Chiron, C., Dulac, O., Luna, D., Palacios, L., Mondragon, S., Beaumont, D., Mumford, J.P. Lancet (1990) [Pubmed]
  3. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Chadwick, D. Lancet (1999) [Pubmed]
  4. Improvement of stiff-man syndrome with vigabatrin. Vermeij, F.H., van Doorn, P.A., Busch, H.F. Lancet (1996) [Pubmed]
  5. Bipolar affective psychosis after vigabatrin. Naumann, M., Supprian, T., Kornhuber, J., Lange, K.W., Reiners, K. Lancet (1994) [Pubmed]
  6. Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update. Browne, T.R., Mattson, R.H., Penry, J.K., Smith, D.B., Treiman, D.M., Wilder, B.J., Ben-Menachem, E., McBride, R.G., Sherry, K.M. Neurology (1991) [Pubmed]
  7. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Stahl, S.M., Thornton, J.E., Simpson, M.L., Berger, P.A., Napoliello, M.J. Biol. Psychiatry (1985) [Pubmed]
  8. Anxiolytic effects of vigabatrin in panic disorder. Zwanzger, P., Baghai, T., Boerner, R.J., Möller, H.J., Rupprecht, R. Journal of clinical psychopharmacology. (2001) [Pubmed]
  9. Vigabatrin and posttraumatic stress disorder. Macleod, A.D. Journal of clinical psychopharmacology. (1996) [Pubmed]
  10. Reversibility of vigabratin-induced visual-field defect. Versino, M., Veggiotti, P. Lancet (1999) [Pubmed]
  11. Long follow-up of tuberous sclerosis treated with vigabatrin. Marciani, M.G., Gigli, G.L., Orlandi, L. Lancet (1992) [Pubmed]
  12. Vigabatrin for startle-disease with altered cerebrospinal-fluid free gamma-aminobutyric acid. Stephenson, J.B. Lancet (1992) [Pubmed]
  13. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Duboc, A., Hanoteau, N., Simonutti, M., Rudolf, G., Nehlig, A., Sahel, J.A., Picaud, S. Ann. Neurol. (2004) [Pubmed]
  14. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Weiss, K.L., Schroeder, C.E., Kastin, S.J., Gibson, J.P., Yarrington, J.T., Heydorn, W.E., McBride, R.G., Sussman, N.M., Arezzo, J.C. Neurology (1994) [Pubmed]
  15. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Grant, S.M., Heel, R.C. Drugs (1991) [Pubmed]
  16. GABA(A)-mediated toxicity of hippocampal neurons in vitro. Lukasiuk, K., Pitkänen, A. J. Neurochem. (2000) [Pubmed]
  17. Ocular adverse effects associated with systemic medications : recognition and management. Santaella, R.M., Fraunfelder, F.W. Drugs (2007) [Pubmed]
  18. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis? Bandini, F., Castello, E., Mazzella, L., Mancardi, G.L., Solaro, C. J. Neurol. Neurosurg. Psychiatr. (2001) [Pubmed]
  19. Visual impairment in children with epilepsy treated with vigabatrin. Gross-Tsur, V., Banin, E., Shahar, E., Shalev, R.S., Lahat, E. Ann. Neurol. (2000) [Pubmed]
  20. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Haegele, K.D., Schechter, P.J. Clin. Pharmacol. Ther. (1986) [Pubmed]
  21. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. French, J.A., Mosier, M., Walker, S., Sommerville, K., Sussman, N. Neurology (1996) [Pubmed]
  22. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Miller, N.R., Johnson, M.A., Paul, S.R., Girkin, C.A., Perry, J.D., Endres, M., Krauss, G.L. Neurology (1999) [Pubmed]
  23. Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ergezinger, K., Jeschke, R., Frauendienst-Egger, G., Korall, H., Gibson, K.M., Schuster, V.H. Ann. Neurol. (2003) [Pubmed]
  24. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ziemann, U., Lönnecker, S., Steinhoff, B.J., Paulus, W. Ann. Neurol. (1996) [Pubmed]
  25. Regulation of GAD expression in rat pancreatic islets and brain by gamma-vinyl-GABA and glucose. Petersen, J.S., Rimvall, K., Jørgensen, P.N., Hasselager, E., Moody, A., Hejnaes, K., Clausen, J.T., Dyrberg, T. Diabetologia (1998) [Pubmed]
  26. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Petroff, O.A., Rothman, D.L., Behar, K.L., Mattson, R.H. Neurology (1996) [Pubmed]
  27. Vigabatrin increases human brain homocarnosine and improves seizure control. Petroff, O.A., Mattson, R.H., Behar, K.L., Hyder, F., Rothman, D.L. Ann. Neurol. (1998) [Pubmed]
  28. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Nath, A., Haughey, N.J., Jones, M., Anderson, C., Bell, J.E., Geiger, J.D. Ann. Neurol. (2000) [Pubmed]
  29. Pharmacokinetic interactions of the new antiepileptic drugs. Rambeck, B., Specht, U., Wolf, P. Clinical pharmacokinetics. (1996) [Pubmed]
  30. Plasticity of rat central inhibitory synapses through GABA metabolism. Engel, D., Pahner, I., Schulze, K., Frahm, C., Jarry, H., Ahnert-Hilger, G., Draguhn, A. J. Physiol. (Lond.) (2001) [Pubmed]
  31. Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H(+)-coupled amino-acid transporter hPAT1. Abbot, E.L., Grenade, D.S., Kennedy, D.J., Gatfield, K.M., Thwaites, D.T. Br. J. Pharmacol. (2006) [Pubmed]
  32. Vigabatrin-induced modification of Ki-67 expression in gingival epithelium: immunohistochemical study of a short series. Mesa, F., Aguilar, M., Gonzalez-Moles, M.A., Guerrero, A., Sanchez-Alvarez, J.C., Del Moral, R.G., O'Valle, F. J. Periodont. Res. (2004) [Pubmed]
  33. Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Gropman, A. Ann. Neurol. (2003) [Pubmed]
  34. Effect of vigabatrin on glutamate dehydrogenase in the hippocampus of seizure prone gerbils. Kang, T.C., An, S.J., Park, S.K., Hwang, I.K., Choi, S.Y., Kwon, O.S., Won, M.H. Neurosci. Lett. (2003) [Pubmed]
  35. Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA). Matern, D., Lehnert, W., Gibson, K.M., Korinthenberg, R. J. Inherit. Metab. Dis. (1996) [Pubmed]
  36. Outer retinal dysfunction in patients treated with vigabatrin. Arndt, C.F., Derambure, P., Defoort-Dhellemmes, S., Hache, J.C. Neurology (1999) [Pubmed]
WikiGenes - Universities